Gubra stock has been on a tear in recent months, closing at DKK390.2 and sitting on a double digit gain over 30 and 90 days. Yet the fresh H1 2026 report tells a tougher story on the income statement, with revenue of DKK126.3m sitting beside a net loss of DKK110.0m.

The real headline is not this half year loss. It is the tension between heavy investment in obesity and peptide drug discovery on one side and a valuation that already prices in a lot of future success on the other. Short term traders are watching the red ink. Long term holders are weighing the pipeline and multi year growth forecasts.

Is Gubra a deep value opportunity given the large gap between the current DKK390.2 share price and the DCF estimate, or are investors…